Earnings date: August 5, 2026
Company: Insulet
Ticker: PODD
Primary debate: Whether strong Omnipod demand is intact despite manufacturing corrections, tougher comparisons, and increasing competition.
Insulet enters Q2 with a sharp disconnect between operating performance and the share price. Q1 revenue grew 30% in constant currency, management raised full-year revenue guidance, and adjusted EPS increased roughly 40%. Yet PODD closed August 4 at $166.85, down approximately 41% from January 2 and essentially unchanged from the day before its Q1 report.
That suggests the market is looking beyond a simple quarterly beat. The report needs to establish three things:
A revenue beat without reassuring commentary on these issues may not be enough.
Insulet’s Q2 guidance, issued May 6, was:
| Metric | Q2 2026 guidance |
|---|---|
| U.S. Omnipod growth | 18%–20% constant currency |
| International Omnipod growth | 28%–30% constant currency |
| Total Omnipod growth | 21%–23% constant currency |
| Total company growth | 20%–22% constant currency |
| Expected FX benefit | Approximately 1 point to total growth; 2 points internationally |
Applied to Q2 2025 results, guidance implies approximately:
| Metric | Implied Q2 2026 reported result |
|---|---|
| Total revenue | $785M–$798M |
| U.S. Omnipod revenue | $535M–$544M |
| International Omnipod revenue | $242M–$245M |
| Total Omnipod revenue | $780M–$792M |
| Drug Delivery revenue | Approximately $5M |
The U.S. comparison deserves context. About $10 million of distributor orders shifted from Q2 into Q1, creating an estimated two-percentage-point headwind to Q2 growth. Thus, the guidance effectively assumes underlying U.S. growth closer to 20%–22%.
A high-quality result would therefore include total revenue above the upper end of guidance, underlying U.S. growth above 22%, and international growth above the guided 28%–30% constant-currency range.
Q1 U.S. Omnipod revenue grew 28%, or approximately 26% excluding the distributor-order timing benefit. New-customer starts increased year over year but declined sequentially as deductible resets created greater-than-normal seasonality. Management said trends improved each month and continued strengthening into April.
Investors should focus on:
A reported 18%–20% U.S. growth rate would be acceptable under guidance, but commentary on underlying demand will determine how investors interpret it.
Type 2 represented approximately 40% of U.S. new-customer starts in Q1. Management estimates AID penetration in insulin-using type 2 patients remains around 5%, versus roughly 55% CGM penetration, leaving a substantial conversion opportunity.
The concern is retention. Insulet has said type 2 users show similar utilization to type 1 users once established, but somewhat higher early attrition because onboarding and adaptation require more support.
Key disclosures would include:
Stable aggregate retention near the roughly 90% level cited last quarter would be reassuring.
International Omnipod revenue grew 45% in constant currency in Q1, the third consecutive quarter above 40%. Q2 guidance calls for a deceleration to 28%–30%.
Management attributes that moderation to:
Importantly, management expected international revenue dollars to continue rising sequentially on a constant-currency basis.
Investors should distinguish benign comparison-driven deceleration from weakening new-customer activity. Growth above 30%, combined with healthy starts in the U.K., France, and Germany, would materially improve the report.
Other items to watch include:
Insulet has announced two separate voluntary medical-device corrections in 2026 involving cannula tears associated with handling processes at its Acton facility.
The May action occurred after Q1 and will therefore be a central Q2 issue. Investors need clarity on:
Management reported in June that physician discussion of the issue had been limited and that no commercial disruption was evident. Confirmation through Q2 operating data would be more persuasive.
Adjusted numbers will remove these costs, but investors should not treat them as economically irrelevant. Repeated quality actions can affect regulatory risk, brand trust, manufacturing efficiency, and future margins.
Insulet launched its most significant Omnipod 5 algorithm update since the product’s 2022 introduction. The update includes:
Libre 3 Plus opens Omnipod 5 to an estimated 450,000 U.S. Libre 3 Plus users. Management needs to explain whether the integration was fully available during Q2 and when a meaningful new-start contribution should appear.
Insulet expanded its U.S. sales force by approximately 25%, increasing coverage and allowing more frequent physician engagement. Because hiring, training, and territory development take time, management previously indicated that the full benefit should be more visible in 2027.
For Q2, investors should look for early indicators such as:
The STRIVE study supported Omnipod 6’s safety and next-generation algorithm performance. Among well-controlled Omnipod 5 users, the system produced:
Omnipod 6 remains planned for 2027. It will also feature a more flexible pod-to-CGM connection and over-the-air pod configuration, potentially simplifying inventory and manufacturing.
The EVOLVE pivotal trial is underway, with a planned 510(k) submission in 2027 and commercial launch targeted for 2028. The investigational system is designed to require no meal boluses and no physician-entered settings—an important potential differentiator for primary-care adoption.
This pipeline is not likely to drive the Q2 numbers, but maintaining the timelines is important to the long-term growth case.
Q1 adjusted operating margin expanded 110 basis points to 17.5%, despite elevated R&D and commercial investment. Adjusted gross margin was 71%, but was reduced by more than 150 basis points of excess and obsolete inventory costs as Insulet transitioned to new pod configurations.
Current full-year targets are:
| Metric | FY2026 outlook |
|---|---|
| Adjusted operating margin | Approximately 100 bps of expansion |
| Implied adjusted operating margin | Approximately 18.6%, versus 17.6% in 2025 |
| Adjusted EPS growth | More than 25% |
| Implied adjusted EPS floor | More than approximately $6.21, versus $4.97 in 2025 |
| Free cash flow | Approximately flat with 2025 |
Q2 margin considerations include:
Potential positives
Potential offsets
At $166.85, PODD trades at less than 27 times the minimum EPS implied by management’s “greater than 25%” growth target. That is not a consensus valuation, but it illustrates how substantially the stock has derated. Maintaining the margin and EPS outlook is therefore likely more important than the precise Q2 adjusted EPS figure.
After Q1, Insulet raised total-company constant-currency revenue growth guidance by one percentage point:
| Metric | Current FY2026 guidance |
|---|---|
| U.S. Omnipod | 20%–22% |
| International Omnipod | 26%–28% |
| Total Omnipod | 22%–24% |
| Total company | 21%–23% |
| Reported total-company growth including FX | 22%–24% |
| Adjusted operating-margin expansion | Approximately 100 bps |
| Adjusted EPS growth | More than 25% |
At the midpoint, this implies total 2026 revenue of roughly $3.33 billion.
Management acknowledged that the existing outlook implies growth moderating into the high teens in the second half. Investors have questioned how that exit rate reconciles with the company’s long-term target of approximately 20% annual growth.
A guidance raise would be positive but is not essential. Given the May correction and tougher second-half comparisons, a credible reiteration accompanied by strong customer metrics could be enough. Conversely, a reduction in U.S. or margin guidance would reinforce concerns that the Q1 strength was not sustainable.
The numerical hurdle appears manageable: approximately $785 million–$798 million of Q2 revenue, with a reasonable chance of upside if the demand trends discussed in May persisted. But this is primarily a quality, durability, and guidance quarter rather than a conventional beat-or-miss event.
The most constructive report would combine:
Given the stock’s roughly 41% year-to-date decline, credible evidence that the core Omnipod franchise remains a durable 20% grower could drive a meaningful re-rating. Another quality surprise or any weakening in U.S. demand would likely outweigh an otherwise acceptable adjusted earnings result.